Abl, active

N-terminal 6His-tagged recombinant, human Abl, amino acids 27-end.

Catalog #: 14-529


Biological Information
Background Information:
The abl oncogene was initially identified as the viral transforming gene (v-abl) of Abelson murine leukemia virus (A-MuLV), from a chemically thymectomized mouse inoculated with Moloney murine leukemia virus (M-MuLV). The v-abl genome consists of M-MuLV gag sequences fused to mouse c-abl, resulting in the production of phosphoproteins, p160 and p120 gag/c-abl with protein-tyrosine kinase activity, as the major translational products. The abl oncogene is implicated in serval human leukemias including chronic myelocytic (CML), adult acute lymphoblastic (ALL) and pediatric ALL. In these leukemias the c-abl proto-oncogene undergoes a chromosomal translocation producing the Philadelphia (;) chromosome resulting in the fusion of c-abl sequences to the bcr gene of chromosome 22, and the molecular consequences of this translocation is the generation of a chimeric bcr/c-abl mRNA encoding activated abl protein-tyrosine kinase. GenBank U07563
Target Class:
Accession Number:
NM_005157.3; NM_007313.2
Target Name:
Target Aliases:
ABL1, JTK7, p150, bcr/abl, v-abl, c-ABL, ABL
Target Species:
Product Type:
Drug Discovery & Development
Storage Conditions:
6 months at -70°C
Usage Disclaimer:
These products may be covered by issued US and/or foreign patents, patent application and subject to Limited Use Label License. Please visit discoverx.com/license for a list of products that are governed by limited use label license terms and relevant patent and trademark information.


14-529x Datasheet

View Document